For instance, modified FGF19 has been shown to be beneficial in mouse models of MASH and cholestasis,21,22 suggesting a therapeutic possibility in using this target to treat MASH in humans. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.